Abstract
Background: Predictive molecular markers based on the consensus molecular classification of colorectal carcinoma are tested following expert recommendations. Specifically, they are tested when target molecular therapy is being considered for treatment. Their presence depends on biology but their frequency seems to be increased in advanced stages. Objective: We developed a study of cases of left-sided CRC in advanced clinical stages from a cohort of Mexican patients to evaluate the presence of predictive molecular markers. Method: Predictive molecular markers were analyzed, including BRAF, KRAS, NRAS and mismatch repair genes, in cases of advanced, left-sided colorectal carcinoma.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
